On April 23, we suggested investors take a bullish posture on NVO, the maker of Ozempic (a popular diabetes therapy) and Wegovy (the popular weight loss drug). This article is for paid members - please login or subscribe for access. Username Password Remember Me Forgot Password Share: Mark W. Guthner, CFA Previous Post Apple Inc: AAPLNext PostDollar General: DG You Might Also Like Freeport McMoRan (FCX) June 16, 2021 Rio Tinto as a Debasement Trade | RIO October 14, 2025 Marriott International: MAR August 20, 2022
You Might Also Like Freeport McMoRan (FCX) June 16, 2021 Rio Tinto as a Debasement Trade | RIO October 14, 2025 Marriott International: MAR August 20, 2022
